Lyell Immunopharma (LYEL) Shares Issued (2020 - 2021)

Lyell Immunopharma (LYEL) reported Shares Issued of $43.6 million for Q3 2021, up 3.28% sequentially from $42.2 million in Q2 2021.

Lyell Immunopharma (LYEL) Shares Issued (2020 - 2021) Analysis & Trends

Lyell Immunopharma (LYEL) has 2 years of Shares Issued data on file, last reported at $43.6 million in Q3 2021.

For the quarter ending Q3 2021, Shares Issued changed N/A year-over-year to $43.6 million; the trailing twelve-month figure through Sep 2021 stood at $43.6 million (changed N/A YoY), and the FY2020 full-year result was $34.4 million, changed N/A from the prior year.
Shares Issued improved to $43.6 million in Q3 2021, from $42.2 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $43.6 million in Q3 2021 to a low of $34.4 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Shares Issued (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	19.44 Mn
10	Lyell Immunopharma	298.14 Mn	298.14 Mn	-	-

Download Data